H eart failure is a global problem, with an estimated prevalence of 38 million patients worldwide, and a major cause of morbidity and mortality despite advances in cardiovascular therapy throughout the past decades (1, 2) . Among the various etiologies of heart failure, dilated cardiomyopathy (DCM) is a common cause. DCM is typically diagnosed by left ventricular dilation and impaired systolic function without any known cause (e.g., pressure overload or coronary artery disease) sufficient to explain the myocardial dysfunction (3) .
Common pharmacological and device therapies such as b-blockers, renin-angiotensin-aldosterone system inhibitors, and cardiac resynchronization therapy induce left ventricular reverse remodeling (LVRR), characterized by a decrease in left ventricular volume and improvement in systolic function in a certain population of patients with DCM (4) . In many clinical trials studying patients with DCM, mortality rates decreased with increasing left ventricular ejection fraction (LVEF) and decreasing left ventricular enddiastolic and end-systolic volumes (4) (5) (6) .
The potential for left ventricular recovery is probably intrinsically conserved in the setting of cardiac WGA = wheat germ agglutinin dysfunction, and even in the presence of apparently severe myocardial dysfunction (7) . However, the recovery of left ventricular function is not universal, occurring in only about 40% of patients with DCM (4, 5) . Therefore, a major unmet need in the clinical setting is the identification of patients who retain this potential for heart function recovery. Even in the United States, a shortage of donor hearts is a critical problem. Over the past 2 decades, there have been increasingly long waiting times for heart transplantation because the number of available hearts has decreased substantially, from 38% in 2000 to 32% in 2010 (8) . In Japan, DCM is the primary cause of endstage heart failure requiring heart transplantation.
The waiting time for patients is much longer in Japan than in other countries, and a substantial proportion of patients die while on the waiting list.
If we can anticipate the patients unlikely to achieve remodeling, then these patients can be preferentially referred for mechanical circulatory support and heart transplantation at an earlier stage. The longterm management and prognostic stratification of patients with DCM would benefit from the identification of reliable clinical predictors of LVRR to optimize the treatment strategy and improve patient prognosis.
Many studies have attempted to identify a predictor of LVRR in patients with DCM (9) (10) (11) . At present, hemodynamic parameters such as blood pressure, echocardiographic parameters such as left ventricular end-diastolic diameter, and interstitial fibrosis evaluated by late gadolinium enhancement of cardiac magnetic resonance are reported as useful predictors of LVRR. However, common examinations such as blood pressure measurement and echocardiography are not strong predictors of LVRR. Likewise, late gadolinium enhancement evaluation by cardiac magnetic resonance is burdened with the issue of false positives and cannot be performed in patients with renal dysfunction. Therefore, we still lack an accurate method to predict LVRR in patients with DCM (7) .
In previous studies of animal models, accumulation of unrepaired oxidative DNA damage was observed in the failing heart (12, 13) . Our group has previously reported that the accumulation of unrepaired DNA single-strand breaks plays a causative role in the pathogenesis of heart failure (14) .
Furthermore, using single-cardiomyocyte RNA sequencing, we have also reported that p53 in cardiomyocytes increases cell-to-cell transcriptional heterogeneity and drives pathogenic gene programs, which shows how the accumulation of DNA damage leads to heart failure (15) . However, all of these studies were conducted using animal models, and there have been few studies on DNA damage in human heart failure.
Poly(ADP-ribose) (PAR) is a major marker of DNA damage; it solely regulates diverse biological processes known as DNA damage responses (16) . The DNA damage responses include DNA repair, chromatin remodeling, transcription, and cell death (17) . A recent report by Hoch et al. (18) has shown that PAR in brain tissues could reflect the disease severity of cerebellar ataxia caused by a mutation of XRCC1, a gene involved in DNA single-strand break repair. This report raises the possibility that PAR staining could be used to measure DNA damage in human tissues. In the present study, we conducted immunofluorescence staining of PAR in endomyocardial biopsy specimens obtained from patients with DCM to confirm whether there is a DNA damage signature in the failing human heart. We also aimed to verify the utility of immunostaining of DNA damage markers for the prediction of response to heart failure therapy in patients with DCM.
METHODS
STUDY POPULATION AND DESIGN. We retrospectively enrolled patients who were diagnosed with DCM and underwent endomyocardial biopsy between 2009 and 2016 at the University of Tokyo Hospital, a tertiary referral center in Japan for cardiomyopathies.
No statistical methods were used to estimate a priori sample size. The DCM diagnosis was made according to current guidelines and based on various modalities including coronary angiography, echocardiography, and endomyocardial biopsy (19, 20) . As this study is intended to evaluate the utility of immunostaining DNA damage markers in biopsy specimens for the prognostic stratification of patients, patients who have already received optimal medical therapy at the time of biopsy were excluded. According to the gen- All analyses were carried out using SAS software version 9.4 (SAS Institute, Inc., Cary, North Carolina).
For all tests, a probability value of p < 0.05 was considered significant.
RESULTS

CHARACTERISTICS OF THE STUDY POPULATION.
A total of 82 patients underwent endomyocardial biopsy and were diagnosed with DCM during the study period. Among these, 24 (29.9%) patients were excluded mainly because they had already received full administration of optimal medical therapy with In this study, we used age, BMI, family history, duration of heart failure, NYHA functional classification, systolic blood pressure, BNP, left ventricular end-diastolic diameter, and severe mitral regurgitation (grade III or IV) as confounders for adjustment in propensity score analysis. Propensity score analysis for combined endpoint revealed that %PAR nuclei (for every 10% increase, hazard ratio: 1.36; 95% confidence interval [CI]: 1.02 to 1.81; p ¼ 0.035) was a significant and independent prognostic factor after adjustment for other major clinical factors ( Table 2) .
Other major prognostic factors predicting poor outcome in univariable Cox analysis were age, high NYHA functional class, low blood pressure, and low BMI. Because only a small number of patients in our cohort had undergone cardiac magnetic resonance (27.6%) and cardiopulmonary exercise testing (51.7%), we could not include late gadolinium enhancement extent and peak oxygen consumption in the model of propensity score analysis. The %PAR nuclei (for every 1% increase, odds ratio: 0.87; 95% CI: 0.79 to 0.95; p ¼ 0.003) was also identified by propensity score analysis as a significant independent predictor of LVRR ( Table 3 ). The results of the same analysis using the data for g-H2A.X staining are shown in Tables 2 and 3 , which revealed that %g-H2A.X-stained nuclei can also independently predict LVRR. Figure 5 shows the results of the ROC analysis.
Compared with g-H2A.X staining, PAR staining showed an incremental prognostic power for LVRR, but the statistical difference between these 2 models was not significant (p ¼ 1.000). The ideal cutoff value of %PAR nuclei to predict LVRR in our study cohort was 5.74%. Using this threshold, the %PAR nuclei predicted LVRR with a sensitivity of 77.8% (95% CI: 57.7% to 91.4%) and a specificity of 87.1% (95% CI: 70.2% to 96.4%), and the area under the ROC curve was 0.879. Abbreviations as in Figure 1 . is slightly better than that of g-H2A.X. A previous study involving a small number of patients with heart failure (not limited to DCM) showed that mechanical unloading by LVAD implantation reduced DNA damage responses (26) . Taken together with our results, DNA damage seems to be a very important pathophysiological component of heart failure. DCMcausative genes encode a heterogeneous group of molecules that participate in force generation, force transmission, sarcomere integrity, and cytoskeletal and nuclear architecture (27) . We have previously reported the prognostic value of genetic mutations in Japanese patients with DCM (28) . At first glance, it looks like the majority of DCM-causative genes such as sarcomere and cytoskeletal genes have no relationship with DNA damage. However, the linker of the nucleoskeleton and cytoskeleton complex physically couples the nuclear membrane with the cytoskeleton (29) . Therefore, sarcomere and cytoskeletal impairment may also have a harmful impact on the nucleus. Although we do not know the genetic mutations among our study population, the significantly high proportions of PAR-positive nuclei seen in poorprognosis patients suggests that the accumulation of DNA damage is a common pathogenetic trait in severe Second, the sample size in our study population is small and, as mentioned before, we could not include the extent of late gadolinium enhancement or peak oxygen consumption in the propensity score analysis, which makes it impossible to compare % PAR nuclei with these gold standards for assessing prognosis. Third, although we paid careful attention to the immunofluorescence staining of the endomyocardial biopsy specimens, this process requires effort and time. Besides, the results of immunostaining will be affected by many factors such as the quality of antibodies, the storage conditions of endomyocardial biopsy specimens, and the technical skills of the staff. Therefore, simpler methods to measure DNA damage should be developed.
CONCLUSIONS
In this study, we demonstrated the utility of PAR staining to predict the probability of LVRR. Our 
